![](/img/cover-not-exists.png)
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer
Petrylak, Daniel P., Gandhi, Jitendra G., Clark, William R., Heath, Elisabeth, Lin, Jianqing, Oh, William K., Agus, David B., Carthon, Bradley, Moran, Susan, Kong, Ning, Suri, Ajit, Bargfrede, MichaelVolume:
33
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-014-0199-x
Date:
April, 2015
File:
PDF, 346 KB
english, 2015